(Guest Lecture) Mezigdomide (CC-92480) | Paul Richardson, MD | ASH 2022

Individualized Prediction Model in Myeloma & Genome Sequencing | Francesco Maura, MD | ASH 2022

MODAKAFUSP ALFA (TAK-573) | Dan Vogl, MD, MSCE | ASH 2022

Opioid Use in Managing Pain in Myeloma | Karen Sweiss, PharmD | ASH 2022

Frailty and Multiple Myeloma | Hira Mian, MD, MSc | ASH 2022

MajesTEC-2 Trial | Emma Searle, MBChB MA MRCP FRCPath PhD | ASH 2022

Barriers to Participation in Hematology Trials | Shakira Grant, MBBS & Jiona Mills | ASH 2022

Talquetamab | Ajai Chari, MD | ASH 2022

OPTIMUM MUK Nine Trial | Martin Kaiser, MD | ASH 2022

How to Better Diagnose Patients With High-Risk Myeloma | Martin Kaiser, MD | ASH 2022

Waitlists for CAR-T | Samer Al'Hadidi, MD | ASH 2022

The Need for New Clinical Trial Strategies | Hearn J. Cho, MD | ASH 2022

Advancements in Immunotherapy Agents | Hearn J. Cho, MD | ASH 2022

LINKER-MM1 Study in RRMM | Naresh Bumma, MD | ASH 2022

Nutrivention Trials | Urvi Shah, MD | ASH 2022

Building a Dietary Evidence Symposium | Urvi Shah, MD | ASH 2022

T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022

Bispecifics | Urvi Shah, MD | ASH 2022

CAR-T Therapy | Santiago Thibaud, MD | ASH 2022

CAR-T BMS-986354 | Luciano Costa, MD, PhD | ASH 2022

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022